Login / Signup

From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy.

Riccardo GiampieriPina ZiranuBruno DanieleAntonio ZizziDaris FerrariSara LonardiAlberto ZaniboniLuigi CavannaGerardo RosatiMariaelena CasagrandeNicoletta PellaLaura DemurtasMaria Giulia ZampinoPietro SozziValeria PuscedduDomenico GermanoEleonora LaiVittorina ZagonelCarla CodecàMichela LibertiniMarco PuzzoniRoberto LabiancaStefano CascinuMario Scartozzi
Published in: Cancers (2020)
Our pre-planned, prospective analysis suggests that circulating FGF-2 levels' early increase could be used as a marker to identify patients who are more likely to gain benefit from FOLFIRI/bevacizumab first-line therapy.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • metastatic colorectal cancer
  • peritoneal dialysis
  • endothelial cells
  • mesenchymal stem cells
  • patient reported
  • cell therapy